LEVOSIMENDAN
Get in touch with us!
An overview
Levosimendan is indicated for the short-term treatment of acute severe decompensation of chronic heart failure in situations where conventional treatment is not sufficient, and in cases where inotropic support is considered appropriate.
- Product Type: Cardiac therapy, cardiac stimulant
- CAS Number: 141505-33-1
- Common Indications: Calcium sensitizer used in the management of acute heart failure
- Product Status: Commercial
- Available Grades: Non-Micronized
- Documentation: DMF, CoA, MSDS
Advantages
Efficacy:
Much higher therapeutic adherence
Very wide antibiotic spectrum of action
Activity against Neisseria meningitidis.
Used to treat multidrug-resistant.
Safety:
Better pharmacokinetic profile.
Longer half-life than Tetracycline.
FDA and European approval for the treatment of infections.
Low development of resistance in bacteria.
Finished
Dosage Forms
Injectable:
Concentrate for solution for infusion:
2,5 mg/ml
Global market status
0
M
USD global market sales in 2023
0
MT
consumed globally
0
%
Lorem ipsum solor
Few API manufacturers to cover worldwide demand.
Our API
Levosimendan
- Our API Levosimendan is manufactured in accordance with cGMP and stringent international quality standards.
Quality
- Our quality control follows every stage from development of analytical methods to the control of manufacturing process.
Samples availables
MINOCYCLINE
PATENT PROTECTION
